title: Role of interleukin-1 receptor type II in the pathogenesis of endometriosis.
abstract: OBJECTIVE
  To determine the role of interleukin-1 receptor type II (IL-1RII) in the pathogenesis of endometriosis.
  
  
  METHODS
  Cultures of endometrial cells exposed to soluble IL-1RII or the recombinant adenovirus of IL-1RII (rAd-RII).
  
  
  METHODS
  Gynecology clinic and human reproduction research laboratory.
  
  
  METHODS
  Women with endometriosis undergoing hysterectomy.
  
  
  METHODS
  Cell culture media were collected 12 hours after addition of soluble IL-1RII or infection of rAd-RII.
  
  
  METHODS
  The levels of IL-6 and IL-8 in the culture media were measured via enzyme-linked immunoabsorbent assay. Furthermore, proteins of the cells were collected for two-dimensional electrophoresis and the differential protein expression was identified by the matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry.
  
  
  RESULTS
  Addition of soluble IL-1RII (2.0 microg/mL) significantly inhibited IL-1 beta-induced IL-6 and IL-8 secretion by endometrial cells in vitro. Infection of endometrial cells with rAd-RII significantly decreased IL-1 beta-induced IL-8 secretion, compared with the PBS and rAd-LacZ controls but had no significant effect on IL-6 secretion. Proteins of the infected cells were collected for two-dimensional electrophoresis, and intensities of 62 spots were significantly increased or decreased when compared with those in the PBS group. Thirty-four proteins were identified by MALDI-TOF mass spectrometry. The majority of the identified proteins are related to cellular metabolism and proliferation.
  
  
  CONCLUSIONS
  These results suggest that IL-1RII can neutralize IL-1 beta and counteract its effect on endometrial stromal cells, and may provide a new clinical strategy for the treatment of endometriosis.
authors.affiliation: Center of Clinical Reproductive Medicine, Department of Obstetrics and Gynecology, First Affiliated Hospital of Nanjing Medical University, Nanjing, People's Republic of China.
authors.forename: Zhen
authors.initials: Z
authors.lastname: Hou
authors.forename: Jing
authors.initials: J
authors.lastname: Zhou
authors.forename: Xiang
authors.initials: X
authors.lastname: Ma
authors.forename: Lu
authors.initials: L
authors.lastname: Fan
authors.forename: Lianming
authors.initials: L
authors.lastname: Liao
authors.forename: Jiayin
authors.initials: J
authors.lastname: Liu
mesh_terms: D000256:Adenoviridae / Q000235:genetics; D000328:Adult; D002478:Cells, Cultured; D015180:Electrophoresis, Gel, Two-Dimensional; D004715:Endometriosis / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005822:Genetic Vectors; D006801:Humans; D053583:Interleukin-1beta / Q000378:metabolism; D015850:Interleukin-6 / Q000378:metabolism; D016209:Interleukin-8 / Q000378:metabolism; D008875:Middle Aged; D011506:Proteins / Q000378:metabolism; D040901:Proteomics / Q000379:methods; D053574:Receptors, Interleukin-1 Type II / Q000235:genetics / Q000378:metabolism*; D019032:Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; D017154:Stromal Cells / Q000378:metabolism* / Q000473:pathology; D013997:Time Factors; D014162:Transfection
chemical_list: C508592:IL1R2 protein, human; C508600:IL6 protein, human; D053583:Interleukin-1beta; D015850:Interleukin-6; D016209:Interleukin-8; D011506:Proteins; D053574:Receptors, Interleukin-1 Type II